YNIOS PHARMA aims to develop a safe and effective injectable treatment, administered via perfusion, designed to protect against organ failure by supporting vascular integrity and modulating immune response.

Our ongoing R&D program is focused on identifying biomarkers to tailor treatment precisely to the patient’s condition, ensuring optimal outcomes in managing ischemia/reperfusion injuries.

The development strategy is structured and progressive, initially addressing septic shock, followed by applications in solid organ transplantation, including advanced methodologies to optimize treatment efficacy and safety across various clinical scenarios.